Anonymous
Guest
Anonymous
Guest
Guess who's going to be selling orals in your endo offices those 4 months.
NO ONE.
Brilliant.
Hey, here's a question: It was actually somebody's strategy to NOT have the ESS team selling Bydureon in the 1st position? With all these people already on the oral side of the team, that ESS skill has been selling our $0 co-pay card instead? Because there's not a lot of high-level clinical differentiation among the SGLT-2 class.
Hate to be politically incorrect, but that was retarded.